Catalent Invests $350M to Expand Manufacturing Capabilities

Pharmaceutical and biotechnology solutions firm Catalent revealed plans this week to invest $350 million in an expansion of biologics drug substance and drug product manufacturing capabilities at its Bloomington, IN plant.

New 2,000 L single-use bioreactors will be installed during the project and the firm plans to add downstream processing capabilities for drug substance, increasing the versatility of the location. The project also includes new quality control labs and additional packaging space with high-speed cartoning and auto-injector device assembly capabilities.

“We continue to see strong growth in demand for biologics development and manufacturing with a deep pipeline across multiple indications,” Mike Riley, president of Biotherapeutics at Catalent, said in a company release. “These investments will enable us to expand our flagship Bloomington facility and extend our leadership as one of the largest and most comprehensive global centers for integrated manufacturing capabilities. The site offers highly flexible and scalable solutions to companies developing new biological drugs, vaccines, RNA therapies, and other innovative treatments for patients around the world.”

Additionally, Catalent will boost the site’s drug product fill/finish capacity by installing new syringe filling lines under barrier isolator technology and more capacity for lyophilized vials.

An estimated 1,000 new jobs will be created through the company’s investment in the Bloomington site.